Benzinga | Jun 21, 2021 06:05AM EDT

Albireo Announces Expanded Phase 3 Data on Bylvay and A3907 at Upcoming EASL International Liver Congress

-- Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters --

-- Bylvay patient responder data show sustained improvements in cholestasis markers vs. non-responders --

-- A3907, next-generation ASBT inhibitor in Phase 1, represents a promising new therapeutic agent for adult cholestatic liver diseases --